Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY – Get Free Report) saw a significant growth in short interest in the month of July. As of July 31st, there was short interest totaling 23,281 shares, a growth of 157.9% from the July 15th total of 9,026 shares. Based on an average trading volume of 69,598 shares, the short-interest ratio is presently 0.3 days.
Ono Pharmaceutical Trading Down 0.2%
Ono Pharmaceutical stock opened at $5.01 on Friday. The business’s 50-day simple moving average is $4.85 and its 200-day simple moving average is $5.03. Ono Pharmaceutical has a 52 week low of $3.55 and a 52 week high of $5.75.
About Ono Pharmaceutical
Ono Pharmaceutical Co, Ltd. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and marketing of prescription drugs and diagnostics. Headquartered in Osaka, the company traces its origins to the early 18th century and has grown into a global specialty‐pharmaceutical firm. Its product portfolio spans oncology, immunology, allergy and inflammatory diseases, with a notable focus on novel immunotherapies.
In oncology, Ono Pharmaceutical is best known for co‐developing and commercializing nivolumab (Opdivo), an anti–PD‐1 immune checkpoint inhibitor developed in partnership with Bristol‐Myers Squibb.
See Also
- Five stocks we like better than Ono Pharmaceutical
- Why Are Analysts Freaking Out About Apple’s All-Glass iPhone?
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
Receive News & Ratings for Ono Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ono Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
